ABSI · Absci Corporation

Summary

Absci Corporation announced the retirement of Chief Innovation Officer Andreas Busch, Ph.D., effective March 31, 2026, with transition to scientific advisor role, and appointment of Ransi Somaratne, M.D., as Chief Medical Officer effective March 3, 2026. The Board approved amended and restated director and officer indemnification agreements on March 6, 2026.

Key takeaways

• Andreas Busch, Ph.D., Chief Innovation Officer, retires effective March 31, 2026; transitions to scientific advisor for 2-year term starting April 3, 2026
• Dr. Busch advisor compensation: $25,500 annual retainer, 22,800 stock options, 5,800 RSUs
• Amendment to 2,489,290 vested stock options for Dr. Busch: exercise period extended to 3 months post-advisor termination (12 months if death/disability)
• Ransi Somaratne, M.D., appointed Chief Medical Officer effective March 3, 2026
• Board approved A&R Form Indemnification Agreements for all current directors and officers on March 6, 2026; supersede prior agreements
• Press release issued March 3, 2026 announcing executive changes (Exhibit 99.1)